摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-蒽基肼 | 25975-59-1

中文名称
5-蒽基肼
中文别名
雄甾-5-烯二醇
英文名称
3β,17β-dihydroxy-19-norandrost-5-ene
英文别名
19-nor-androst-5-ene-3β,17β-diol;5-estrene-3β,17β-diol;19-norandrostenediol;estr-5-ene-3β,17β-diol;Oestr-5-en-3β,17β-diol;19-nor-androst-5-en-3β,17β-diol;19-Nor-5-androstenediol;(3S,8R,9S,10R,13S,14S,17S)-13-methyl-1,2,3,4,7,8,9,10,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,17-diol
5-蒽基肼化学式
CAS
25975-59-1
化学式
C18H28O2
mdl
——
分子量
276.419
InChiKey
VVUQRXPUVKXAIO-XFUVECHXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    152-157 °C(Solv: ethanol, 95% (64-17-5))
  • 沸点:
    429.2±45.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)
  • 溶解度:
    氯仿(极少量,超声处理)、甲醇(少量溶解)
  • 物理描述:
    Solid

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    20
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:9e4a8cf8690e42d446d2dc1c58f10850
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    First synthesis of a steroid containing an unstable 19-nor-androsta-1,5-dien-3-one system
    摘要:
    Mechanisms involved in the maintenance of human pregnancy and initiation of labour are poorly defined. A novel steroid hormone named estradienolone (ED), and having an unusual 19-nor-androsta- 1,5-dien-3-one system, was previously reported. However, ED is scarcely available from urine, placenta and blood of pregnant women. For this reason, we have synthesized ED in order to verify its proposed structure. Although a 1,5-dien-3-one system had already been described for a C19-steroid (androstane) nucleus (no possible aromatization), the synthesis of the 19-nor-analogue is a major challenge because this system is very sensitive to aromatization. We now describe the successful construction and characterization of this unstable system. Starting from nortestosterone, the synthesis of 17 beta-hydroxy-19-nor-androsta-1,5-dien-3-one (1) is based on a protection of the 5,6-double bond, the introduction of the second 1,2-double bond, the careful recovery of the exo double bond and a final regioselective oxidation or reduction. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2006.02.063
  • 作为产物:
    描述:
    诺龙 在 lithium aluminium tetrahydride 、 potassium tert-butylate 作用下, 以 四氢呋喃正丁醇 为溶剂, 反应 32.0h, 生成 5-蒽基肼
    参考文献:
    名称:
    [EN] PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF
    [FR] ANTAGONISTES DU RÉCEPTEUR DE LA PROGESTÉRONE ET UTILISATIONS CORRESPONDANTES
    摘要:
    本发明涉及一种化合物,其化学式为(I),用作孕激素受体拮抗剂,特别是用于预防和/或治疗癌症或子宫病变。
    公开号:
    WO2011138460A1
点击查看最新优质反应信息

文献信息

  • FLUORESCENCE BASED DETECTION OF SUBSTANCES
    申请人:Russell David
    公开号:US20090230322A1
    公开(公告)日:2009-09-17
    A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.
    一种用于荧光检测物质的方法,该方法包括提供含有属或属氧化核的颗粒,其中一种或多种可选择性地荧光标记的抗体或人特异性肽核酸(PNA)寡聚体,用于结合到物质上,直接或间接地结合到属或金属氧化物的表面;将可能在其表面具有或不具有该物质的基质与这些颗粒接触一段时间,以充分允许抗体/PNA寡聚体与该物质结合;移除那些未与基质结合的颗粒;如果抗体PNA寡聚体未被荧光标记,则将基质与一种或多种能特异性结合抗体和/或物质的荧光剂接触,然后可选择地清洗基质以去除未结合的荧光剂;并用适当的辐射照射基质以显示基质上的荧光剂。
  • [EN] COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES PERMETTANT DE TRAITER LES TROUBLES DU SNC
    申请人:SAGE THERAPEUTICS INC
    公开号:WO2019126761A1
    公开(公告)日:2019-06-27
    Provided herein is a compound of Formula (I-I) or a pharmaceutically acceptable salt thereof, wherein t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 and R13 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    本文提供了一种式(I-I)的化合物或其药用可接受盐,其中t、R7、R3、R9、R6a、R6b、R11a、R11b、R15a、R15b、R16a、R16b、R17a、R17b、R18a、R18b、R19a、R19b、R5a、R5b、R8和R13在此定义。本文还提供了包括式(I-I)化合物的药物组合物以及使用这些化合物的方法,例如在治疗与中枢神经系统相关的疾病中。
  • [EN] AZA-, OXA AND THIA-PREGNAN-20-ONE-3.ALPHA.-OL COMPOUNDS FOR USE IN TREATING CNS DISORDERS<br/>[FR] COMPOSÉS AZA-, OXA ET THIA-PREGNAN-20-ONE-3.ALPHA.-OL S'UTILISANT DANS LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
    申请人:SAGE THERAPEUTICS INC
    公开号:WO2019140272A1
    公开(公告)日:2019-07-18
    Provided herein is a compound of Formula (I-I), or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I-I), and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
    本文提供了一种公式(I-I)的化合物,或其药学上可接受的盐,其中变量在此定义。本文还提供了包含公式(I-I)的化合物的药物组合物,以及使用该化合物的方法,例如用于治疗中枢神经系统相关疾病。
  • Bone anabolic compounds and methods of use
    申请人:——
    公开号:US20030119800A1
    公开(公告)日:2003-06-26
    A variety of bone anabolic compounds are useful for maintaining and/or increasing bone mass, density, and/or strength in mammals. Preferred compounds enhance bone anabolic activity while minimizing or eliminating undesirable feminizing or masculinizing effects.
    多种骨骼增生化合物对于维持和/或增加哺乳动物的骨量、密度和/或强度是有用的。优选的化合物增强骨骼增生活性,同时最小化或消除不良的女性化或男性化效果。
  • Radioimmunoassay agents
    申请人:The Upjohn Company
    公开号:US04013688A1
    公开(公告)日:1977-03-22
    Novel steroid derivatives containing a tyrosine ester amide group linked to an 11-hydroxysteroid alkylene dicarboxylic hemi-ester are described, suitable for iodination with radioactive iodine, useful in radioimmunoassay.
    本文描述了一种含有酪氨酸酯酰胺基团的新型类固醇生物,该基团与11-羟基类固醇烷二羧酸半酯相连,适用于与放射性进行化反应,用于放射免疫测定中。
查看更多

同类化合物

(5β)-17,20:20,21-双[亚甲基双(氧基)]孕烷-3-酮 (5α)-2′H-雄甾-2-烯并[3,2-c]吡唑-17-酮 (3β,20S)-4,4,20-三甲基-21-[[[三(异丙基)甲硅烷基]氧基]-孕烷-5-烯-3-醇-d6 (25S)-δ7-大发酸 (20R)-孕烯-4-烯-3,17,20-三醇 (11β,17β)-11-[4-({5-[(4,4,5,5,5-五氟戊基)磺酰基]戊基}氧基)苯基]雌二醇-1,3,5(10)-三烯-3,17-二醇 齐墩果酸衍生物1 黄麻属甙 黄芪皂苷III 黄芪皂苷 II 黄芪甲苷 IV 黄芪甲苷 黄肉楠碱 黄果茄甾醇 黄杨醇碱E 黄姜A 黄夹苷B 黄夹苷 黄夹次甙乙 黄夹次甙乙 黄夹次甙丙 黄体酮环20-(乙烯缩醛) 黄体酮杂质EPL 黄体酮杂质1 黄体酮杂质 黄体酮杂质 黄体酮EP杂质M 黄体酮EP杂质G(RRT≈2.53) 黄体酮EP杂质F 黄体酮6-半琥珀酸酯 黄体酮 17alpha-氢过氧化物 黄体酮 11-半琥珀酸酯 黄体酮 麦角甾醇葡萄糖苷 麦角甾醇氢琥珀酸盐 麦角甾烷-6-酮,2,3-环氧-22,23-二羟基-,(2b,3b,5a,22R,23R,24S)-(9CI) 麦角甾烷-3,6,8,15,16-五唑,28-[[2-O-(2,4-二-O-甲基-b-D-吡喃木糖基)-a-L-呋喃阿拉伯糖基]氧代]-,(3b,5a,6a,15b,16b,24x)-(9CI) 麦角甾烷-26-酸,5,6:24,25-二环氧-14,17,22-三羟基-1-羰基-,d-内酯,(5b,6b,14b,17a,22R,24S,25S)-(9CI) 麦角甾-8-烯-3-醇 麦角甾-8,24(28)-二烯-26-酸,7-羟基-4-甲基-3,11-二羰基-,(4a,5a,7b,25S)- 麦角甾-7,22-二烯-3-酮 麦角甾-7,22-二烯-17-醇-3-酮 麦角甾-5,24-二烯-26-酸,3-(b-D-吡喃葡萄糖氧基)-1,22,27-三羟基-,d-内酯,(1a,3b,22R)- 麦角甾-5,22,25-三烯-3-醇 麦角甾-4,6,8(14),22-四烯-3-酮 麦角甾-1,4-二烯-3-酮,7,24-二(乙酰氧基)-17,22-环氧-16,25-二羟基-,(7a,16b,22R)-(9CI) 麦角固醇 麦冬皂苷D 麦冬皂苷D 麦冬皂苷 B